David A. Bellnier

Preliminary clinical data on a new photodynamic therapy photosensitizer: 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer

Hector R. Nava, Thomas J. Dougherty, Michele T. Cooper, 2000, BiOS.

Optical methods for in-vivo pharmacokinetics (Invited Paper)

William R. Potter, Thomas J. Dougherty, David A. Bellnier, 1992, Photonics West - Lasers and Applications in Science and Engineering.

Potential new photosensitizers for photodynamic therapy

Joseph R. Missert, Ravindra K. Pandey, Thomas J. Dougherty, 1990, Photonics West - Lasers and Applications in Science and Engineering.

Potentiation of ALA-PDT antitumor activity in mice using topical DMXAA

Ulas Sunar, Allan R. Oseroff, David A. Bellnier, 2009, World Congress of the International Photodynamic Association.

Photodynamic therapy with 3‐(1′‐hexyloxyethyl) pyropheophorbide‐a for early‐stage cancer of the larynx: Phase Ib study

Barbara W. Henderson, Gal Shafirstein, Wei Tan, 2015, Head & neck.

A new finite element approach for near real‐time simulation of light propagation in locally advanced head and neck tumors

Gal Shafirstein, David A. Bellnier, Emily Oakley, 2015, Lasers in surgery and medicine.

Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy

Hector Nava, Allan R. Oseroff, Thomas J. Dougherty, 2005, Cancer Chemotherapy and Pharmacology.

Light Delivery over Extended Time Periods Enhances the Effectiveness of Photodynamic Therapy

Mukund Seshadri, Thomas H. Foster, Barbara W. Henderson, 2008, Clinical Cancer Research.